Targeted nanocarriers for rheumatoid arthritis therapy: current evidence and translational barriers
DOI:
https://doi.org/10.69857/joapr.v14i3.1758Keywords:
Rheumatoid arthritis, autoimmune disease, nanomedicine, biologics, biomarkers, drug delivery, stem cell therapyAbstract
Background: Rheumatoid arthritis (RA) remains a debilitating autoimmune disorder characterized by chronic synovial inflammation and progressive joint destruction. Conventional systemic therapies provide symptomatic relief but often fail to achieve site-specific delivery, leading to adverse effects and limited long-term efficacy. This review appraises the available evidence for the use of targeted nanocarrier drug delivery systems in the treatment of RA and highlights the translational hurdles that hinder their clinical use. Methodology: A search of PubMed, Scopus, and Web of Science (2015-2025) was conducted using the keywords RA, nanocarriers, liposomes, polymeric nanoparticles, and microneedles. Result and Discussion: Liposomal and polymeric nanoparticle systems are emerging nanotechnologies that have demonstrated improved targeting and therapeutic outcomes in preclinical models. In addition, microneedle technologies show potential for less painful delivery through the skin. Conclusion: Despite encouraging results, inconsistent manufacturing reproducibility, limitations in large-scale production, and regulatory uncertainties, among others, remain factors that are slowing the transition to the clinic. Standardization of characterization procedures, validated preclinical models, and well-designed translational research are among the measures this review has identified as necessary to facilitate the transition of nanocarrier-based therapeutics to clinical application in RA.
Downloads
References
Díaz-González F, Hernández-Hernández MV. Rheumatoid arthritis. Medicina Clínica (English Edition), 161, 533–42 (2023) https://doi.org/10.1016/J.MEDCLE.2023.07.008
An X, Yang J, Cui X, Zhao J, Jiang C, Tang M, Dong Y, Lin L, Li H, Wang F. Advances in local drug delivery technologies for improved rheumatoid arthritis therapy. Adv. Drug Deliv. Rev., 209, 115325 (2024) https://doi.org/10.1016/J.ADDR.2024.115325
Chelliah R, Rubab M, Vijayalakshmi S, Karuvelan M, Barathikannan K, Oh DH. Liposomes for drug delivery: Classification, therapeutic applications, and limitations. Next Nanotechnology, 8, 100209 (2025) https://doi.org/10.1016/J.NXNANO.2025.100209
Sultana A, Zare M, Thomas V, Kumar TSS, Ramakrishna S. Nano-based drug delivery systems: Conventional drug delivery routes, recent developments and future prospects. Med. Drug Discov., 15, 100134 (2022) https://doi.org/10.1016/J.MEDIDD.2022.100134
Kurul F, Turkmen H, Cetin AE, Topkaya SN. Nanomedicine: How nanomaterials are transforming drug delivery, bio-imaging, and diagnosis. Next Nanotechnology, 7, 100129 (2025) https://doi.org/10.1016/J.NXNANO.2024.100129
Islam S, Ahmed MMS, Islam MA, Hossain N, Chowdhury MA. Advances in nanoparticles in targeted drug delivery: A review. Results in Surfaces and Interfaces, 19, 100529 (2025) https://doi.org/10.1016/J.RSURFI.2025.100529
Dixit T, Vaidya A, Ravindran S. Polymeric nanoparticles-based targeted delivery of drugs and bioactive compounds for arthritis management. Future Sci. OA, 11 (2025) https://doi.org/10.1080/20565623.2025.2467591
Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. The Lancet, 402, 2019–33 (2023) https://doi.org/10.1016/S0140-6736(23)01525-8
Dai F, Cai Y, Yang S, Zhang J, Dai Y. Global burden of gallbladder and biliary diseases (1990–2021) with healthcare workforce analysis and projections to 2035. BMC Gastroenterology, 25, 249 (2025) https://doi.org/10.1186/S12876-025-03842-X
Su QY, Yang L, Qi XY, Wang MY, Cheng JW, Niu H, Zhang SX. Global, regional, and national burdens of rheumatoid arthritis among people aged 60 years and older from 1990 to 2021: a trend analysis for the Global Burden of Disease Study 2021. Front. Public Health, 13, 1527680 (2025) https://doi.org/10.3389/FPUBH.2025.1527680/BIBTEX
Black RJ, Cross M, Haile LM, Culbreth GT, Steinmetz JD, Hagins H et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol., 5, e594–610 (2023) https://doi.org/10.1016/S2665-9913(23)00211-4
Cao M, Li C, Li M, Lu K, Wu C, Wang J et al. Prevalence and incidence of rheumatoid arthritis in urban China: A national population-based study. Int. J. Rheum. Dis., 28 (2025) https://doi.org/10.1111/1756-185X.70184
Mousavi SE, Nejadghaderi SA, Khabbazi A, Alizadeh M, Sullman MJM, Kaufman JS, Collins GS, Safiri S. The burden of rheumatoid arthritis in the Middle East and North Africa region, 1990–2019. Sci. Rep., 12, 19297 (2022) https://doi.org/10.1038/S41598-022-22310-0
Dowman B, Campbell RM, Zgaga L, Adeloye D, Chan KY. Estimating the burden of rheumatoid arthritis in Africa: A systematic analysis. J. Glob. Health, 2, 020406 (2012) https://doi.org/10.7189/JOGH.02.020406
Germano JL, Reis-Pardal J, Tonin FS, Pontarolo R, Melchiors AC, Fernandez-Llimos F. Prevalence of rheumatoid arthritis in South America: A systematic review and meta-analysis. Ciencia e Saude Coletiva, 26, 5371–82 (2021) https://doi.org/10.1590/1413-812320212611.3.05152020
Bakri FG, Mollin M, Beaumel S, Vigne B, Roux-Buisson N, Al-Wahadneh AM, Alzyoud RM et al. Second report of chronic granulomatous disease in Jordan: Clinical and genetic description of 31 patients from 21 different families, including families from Libya and Iraq. Front. Immunol., 12, 639226 (2021) https://doi.org/10.3389/FIMMU.2021.639226/FULL
Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology: The Official Journal of the International Society for Pathophysiology / ISP, 12, 183 (2005) https://doi.org/10.1016/J.PATHOPHYS.2005.07.005
Hao G, Han S, Xiao Z, Shen J, Zhao Y, Hao Q. Synovial mast cells and osteoarthritis: Current understandings and future perspectives. Heliyon, 10, e41003 (2024) https://doi.org/10.1016/J.HELIYON.2024.E41003
Yuan F, Quan L Dong, Cui L, Goldring SR, Wang D. Development of macromolecular prodrug for rheumatoid arthritis. Adv. Drug Deliv. Rev., 64, 1205–19 (2012) https://doi.org/10.1016/j.addr.2012.03.006
Wu J. The enhanced permeability and retention (EPR) effect: The significance of the concept and methods to enhance its application. Journal of Personalized Medicine, 11, 771 (2021) https://doi.org/10.3390/jpm11080771
Nasra S, Bhatia D, Kumar A. Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment. Nanoscale Adv., 4, 3479–94 (2022) https://doi.org/10.1039/d2na00229a
Damerau A, Gaber T. Modeling rheumatoid arthritis in vitro: From experimental feasibility to physiological proximity. International Journal of Molecular Sciences, 21, 7916 (2020) https://doi.org/10.3390/IJMS21217916
Hitchon CA, El-Gabalawy HS. The synovium in rheumatoid arthritis. Open Rheumatol. J., 5, 107 (2011) https://doi.org/10.2174/1874312901105010107
Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Research & Therapy, 19, 110 (2017) https://doi.org/10.1186/S13075-017-1303-3
Bhowmik S, Ghosh R, Dev A. Advanced disease-responsive materials as intelligent drug delivery systems for rheumatoid arthritis. J. Drug Deliv. Sci. Technol., 115, 107787 (2026) https://doi.org/10.1016/j.jddst.2025.107787
Bai L, Su P. Nanocarrier-based delivery of siRNA therapeutics in rheumatoid arthritis: Immune mechanisms and translational perspectives. Front. Immunol., 16, 1718256 (2025) https://doi.org/10.3389/fimmu.2025.1718256
Wang Q, Qin X, Fang J, Sun X. Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies. Acta Pharm. Sin. B, 11, 1158–74 (2021) https://doi.org/10.1016/j.apsb.2021.03.013
Chauhan K, Jandu JS, Brent LH, Al-Dhahir MA. Rheumatoid arthritis. Rosen and Barkin’s 5-Minute Emergency Medicine Consult: Fifth Edition (2023) https://doi.org/10.1017/chol9780521332866.074
Kim M, Shin M, Zhao Y, Ghosh M, Son YO. Transformative impact of nanocarrier-mediated drug delivery: Overcoming biological barriers and expanding therapeutic horizons. Small Science, 4, 2400280 (2024) https://doi.org/10.1002/SMSC.202400280
Ben Mrid R, Bouchmaa N, Ainani H, El Fatimy R, Malka G, Mazini L. Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis. Biomedicine & Pharmacotherapy, 151, 113126 (2022) https://doi.org/10.1016/J.BIOPHA.2022.113126
Haley RM, von Recum HA. Localized and targeted delivery of NSAIDs for treatment of inflammation: A review. Exp. Biol. Med., 244, 433–44 (2019) https://doi.org/10.1177/1535370218787770
Butoescu N, Seemayer CA, Palmer G, Guerne PA, Gabay C, Doelker E, Jordan O. Magnetically retainable microparticles for drug delivery to the joint: Efficacy studies in an antigen-induced arthritis model in mice. Arthritis Research & Therapy, 11, R72 (2009) https://doi.org/10.1186/AR2701
Infante M, Padilla N, Alejandro R, Caprio M, Della-morte D, Fabbri A, Ricordi C. Diabetes-modifying antirheumatic drugs: The roles of DMARDs as glucose-lowering agents. Medicina, 58, 571 (2022) https://doi.org/10.3390/MEDICINA58050571
Aljabri A, Soliman GM, Ramadan YN, Medhat MA, Hetta HF. Biosimilars versus biological therapy in inflammatory bowel disease: Challenges and targeting strategies using drug delivery systems. Clinical and Experimental Medicine, 25, 107 (2025) https://doi.org/10.1007/S10238-025-01558-6
Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front. Med. (Lausanne), 10, 1089099 (2023) https://doi.org/10.3389/FMED.2023.1089099/BIBTEX
Garcia-Melendo C, Cubiró X, Puig L. Janus kinase inhibitors in dermatology: Part 1 — general considerations and applications in vitiligo and alopecia areata. Actas Dermosifiliogr., 112, 503–15 (2021) https://doi.org/10.1016/J.ADENGL.2021.03.012
Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, Okoroafor CC, Eze SC, Kalu OL, Odoh EC, Nwadike UG, Ogbodo JO, Umeh BU, Ossai EC, Nwanguma BC. Advances in drug delivery systems, challenges and future directions. Heliyon, 9 (2023) https://doi.org/10.1016/J.HELIYON.2023.E17488
Colella F, Garcia JP, Sorbona M, Lolli A, Antunes B, D’Atri D, Barré FPY, Oieni J, Vainieri ML, Zerrillo L, Capar S, Häckel S, Cai Y, Creemers LB. Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents. Journal of Controlled Release, 328, 985–99 (2020) https://doi.org/10.1016/J.JCONREL.2020.08.041
Hua S, de Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: Pathways for translational development and commercialization. Front. Pharmacol., 9, 790 (2018) https://doi.org/10.3389/FPHAR.2018.00790/EPUB
Andretto V, Dusi S, Zilio S, Repellin M, Kryza D, Ugel S, Lollo G. Tackling TNF-α in autoinflammatory disorders and autoimmune diseases: From conventional to cutting edge in biologics and RNA-based nanomedicines. Adv. Drug Deliv. Rev., 201, 115080 (2023) https://doi.org/10.1016/J.ADDR.2023.115080
Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. International Journal of Molecular Sciences, 22, 2719 (2021) https://doi.org/10.3390/IJMS22052719
Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-a therapy in clinical practice: New lessons and future directions in the COVID-19 era. Rheumatology International, 42, 1493–511 (2022) https://doi.org/10.1007/S00296-022-05136-X
Chen Y, Zhang G, Yang Y, Zhang S, Jiang H, Tian K, Arenbaoligao, Chen D. The treatment of inflammatory bowel disease with monoclonal antibodies in Asia. Biomedicine & Pharmacotherapy, 157, 114081 (2023) https://doi.org/10.1016/J.BIOPHA.2022.114081
Tanaka Y. Rheumatoid arthritis. Inflammation and Regeneration, 40, 20 (2020) https://doi.org/10.1186/S41232-020-00133-8
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet., 389, 2328–37 (2017) https://doi.org/10.1016/s0140-6736(17)31472-1
Mayence A, Eynde JJ Vanden. Baricitinib: A 2018 novel FDA-approved small molecule inhibiting Janus kinases. Pharmaceuticals, 12, 37 (2019) https://doi.org/10.3390/PH12010037
Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J. Clin. Pharmacol., 54, 1354–61 (2014) https://doi.org/10.1002/jcph.354
Tanaka Y. Recent progress in treatments of rheumatoid arthritis: An overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology (Oxford), 60, vi12 (2021) https://doi.org/10.1093/RHEUMATOLOGY/KEAB609
Kiełbowski K, Plewa P, Bratborska AW, Bakinowska E, Pawlik A. JAK inhibitors in rheumatoid arthritis: Immunomodulatory properties and clinical efficacy. International Journal of Molecular Sciences, 25, 8327 (2024) https://doi.org/10.3390/IJMS25158327
Kurul F, Turkmen H, Cetin AE, Topkaya SN. Nanomedicine: How nanomaterials are transforming drug delivery, bio-imaging, and diagnosis. Next Nanotechnology, 7, 100129 (2025) https://doi.org/10.1016/J.NXNANO.2024.100129
Mirkin CA, Langer R, Mrksich M, Margolin AA, Petrosko SH, Artzi N. Blueprints for better drugs: The structural revolution in nanomedicine. ACS Nano, 19, 18889–901 (2025) https://doi.org/10.1021/acsnano.5c06380
Chen M, Daddy KA, Xiao Y, Ping Q, Zong L. Advanced nanomedicine for rheumatoid arthritis treatment: Focus on active targeting. Expert Opin. Drug Deliv., 14, 1141–4 (2017) https://doi.org/10.1080/17425247.2017.1372746
Chuang SY, Lin CH, Huang TH, Fang JY. Lipid-based nanoparticles as a potential delivery approach in the treatment of rheumatoid arthritis. Nanomaterials, 8, 42 (2018) https://doi.org/10.3390/nano8010042
Anita C, Munira M, Mural Q, Shaily L. Topical nanocarriers for management of rheumatoid arthritis: A review. Biomedicine & Pharmacotherapy, 141, 111880 (2021) https://doi.org/10.1016/j.biopha.2021.111880
Dejeu IL, Vicaș LG, Marian E, Ganea M, Frenț OD, Maghiar PB, Bodea FI, Dejeu GE. Innovative approaches to enhancing the biomedical properties of liposomes. Pharmaceutics, 16, 1525 (2024) https://doi.org/10.3390/PHARMACEUTICS16121525
Guimarães D, Noro J, Loureiro A, Lager F, Renault G, Cavaco-Paulo A, Nogueira E. Increased encapsulation efficiency of methotrexate in liposomes for rheumatoid arthritis therapy. Biomedicines, 8, 630 (2020) https://doi.org/10.3390/biomedicines8120630
Sahu A, Rathee S, Saraf S, Raikwar S, Das Bidla P, Pawar RS, Jain SK. Development and characterization of leflunomide and resveratrol loaded nanostructured lipid carrier based in-situ hydrogel system for effective management of rheumatoid arthritis. Journal of Pharmaceutical Innovation, 20, 107 (2025) https://doi.org/10.1007/s12247-025-09976-5
Panchal E, Yadav SK, Jain N, Chauhan M, Sharma A. Design and optimization of folate-targeted lipid-polymer hybrid nanoparticles co-encapsulating dexamethasone and curcumin for synergistic anti-inflammatory efficacy in rheumatoid arthritis. Journal of Applied Pharmaceutical Research, 13, 91–113 (2025) https://doi.org/10.69857/joapr.v13i5.1176
ELhabal SF, El-Nabarawi MA, Hassanin SO, Hassan FE, Abbas SS, Gebril SM, Albash R. Transdermal fluocinolone acetonide loaded decorated hyalurosomes cellulose acetate/polycaprolactone nanofibers mitigated Freund’s adjuvant-induced rheumatoid arthritis in rats. Journal of Pharmaceutical Investigation, 55, 113–32 (2024) https://doi.org/10.1007/s40005-024-00693-8
Manca ML, Lattuada D, Valenti D, Marelli O, Corradini C, Fernàndez-Busquets X, Zaru M, Maccioni AM, Fadda AM, Manconi M. Potential therapeutic effect of curcumin loaded hyalurosomes against inflammatory and oxidative processes involved in the pathogenesis of rheumatoid arthritis: The use of fibroblast-like synovial cells cultured in synovial fluid. European Journal of Pharmaceutics and Biopharmaceutics, 136, 84–92 (2019) https://doi.org/10.1016/j.ejpb.2019.01.012
Chu B, Chen D, Ma S, Yang Y, Shang F, Lv W, Li Y. Novel poly(lactic-co-glycolic acid) nanoliposome-encapsulated diclofenac sodium and celecoxib enable long-lasting synergistic treatment of osteoarthritis. J. Biomater. Appl., 39, 221–34 (2024) https://doi.org/10.1177/08853282241258311
Li Y, Chen Q, Wang T, Ji Z, Regmi S, Tong H, Ju J, Wang A. Advances in microneedle-based drug delivery system for metabolic diseases: Structural considerations, design strategies, and future perspectives. Journal of Nanobiotechnology, 23, 350 (2025) https://doi.org/10.1186/S12951-025-03432-9
Guillot AJ, Cordeiro AS, Donnelly RF, Montesinos MC, Garrigues TM, Melero A. Microneedle-based delivery: An overview of current applications and trends. Pharmaceutics, 12, 569 (2020) https://doi.org/10.3390/PHARMACEUTICS12060569
Makvandi P, Kirkby M, Hutton ARJ, Shabani M, Yiu CKY, Baghbantaraghdari Z, Jamaledin R, Carlotti M, Mazzolai B, Mattoli V, Donnelly RF. Engineering microneedle patches for improved penetration: Analysis, skin models and factors affecting needle insertion. Nano-Micro Letters, 13, 93 (2021) https://doi.org/10.1007/s40820-021-00611-9
Abdullah KM, Sharma G, Singh AP, Siddiqui JA. Nanomedicine in cancer therapeutics: Current perspectives from bench to bedside. Molecular Cancer, 24, 169 (2025) https://doi.org/10.1186/S12943-025-02368-W
Mohan N, Nair RPAN, Narayanasamy D. Nanoparticle-integrated transdermal patches: A platform for next-generation drug delivery. Drug Dev. Res., 86, e70164 (2025) https://doi.org/10.1002/DDR.70164
Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomedical Technology, 5, 109–22 (2024) https://doi.org/10.1016/j.bmt.2023.09.001
Addissouky T. Nanocarrier-mediated drug delivery in rheumatoid arthritis: Overcoming therapeutic limitations through targeted approaches. Clinical Orthopaedics and Trauma Care, 6, 1–8 (2024) https://doi.org/10.31579/2694-0248/108
Mühlebach S. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach? Adv. Drug Deliv. Rev., 131, 122–31 (2018) https://doi.org/10.1016/J.ADDR.2018.06.024
Bi Y, Xie S, Li Z, Dong S, Teng L. Precise nanoscale fabrication technologies, the “last mile” of medicinal development. Acta Pharm. Sin. B, 15, 2372–401 (2025) https://doi.org/10.1016/j.apsb.2025.03.040
Hussian T, Nagar L, Saini A, Gulati N, Gupta VK, Dua G, Tripathy S, Dureja H. Regulatory requirements and clinical trials for nanotechnology-based drug delivery systems for the management of COPD. Nanotechnology-Based Innovations in Chronic Obstructive Pulmonary Disease (COPD) Treatment and Management, 443–63 (2026) https://doi.org/10.1016/B978-0-443-43946-9.00024-0
Huang Y, Guo X, Wu Y, Chen X, Feng L, Xie N, Shen G. Nanotechnology’s frontier in combatting infectious and inflammatory diseases: Prevention and treatment. Signal Transduction and Targeted Therapy, 9, 34 (2024) https://doi.org/10.1038/s41392-024-01745-z
Su S, Kang PM. Recent advances in nanocarrier-assisted therapeutics delivery systems. Pharmaceutics, 12, 837 (2020) https://doi.org/10.3390/PHARMACEUTICS12090837
Crintea A, Dutu AG, Sovrea A, Constantin AM, Samasca G, Masalar AL, Ifju B, Linga E, Neamti L, Tranca RA, Fekete Z, Silaghi CN, Craciun AM. Nanocarriers for drug delivery: An overview with emphasis on vitamin D and K transportation. Nanomaterials, 12, 1376 (2022) https://doi.org/10.3390/NANO12081376
Zhao L, Huang J, Fan Y, Li J, You T, He S, Xiao G, Chen D. Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis. Ann. Rheum. Dis., 78, 676–82 (2019) https://doi.org/10.1136/annrheumdis-2018-214724
Wang S, Wang Y, Chen Q. Nanotechnology-driven strategies for gene therapy of arthritis. Mater. Today Bio, 35, 102301 (2025)https://doi.org/10.1016/J.MTBIO.2025.102301
Wen J, Li H, Dai H, Hua S, Long X, Li H, Ivanovski S, Xu C. Intra-articular nanoparticles based therapies for osteoarthritis and rheumatoid arthritis management. Mater. Today Bio, 19, 100597 (2023) https://doi.org/10.1016/J.MTBIO.2023.100597
Song P, Yang C, Thomsen JS, Dagnæs-Hansen F, Jakobsen M, Brüel A, Deleuran B, Kjems J. Lipidoid-siRNA nanoparticle-mediated IL-1β gene silencing for systemic arthritis therapy in a mouse model. Molecular Therapy, 27, 1424–35 (2019) https://doi.org/10.1016/j.ymthe.2019.05.002
Han X, Liao R, Li X, Zhang C, Huo S, Qin L, Xiong Y, He T, Xiao G, Zhang T. Mesenchymal stem cells in treating human diseases: Molecular mechanisms and clinical studies. Signal Transduction and Targeted Therapy, 10, 262 (2025) https://doi.org/10.1038/s41392-025-02313-9
Mahla RS. Stem cells applications in regenerative medicine and disease therapeutics. Int. J. Cell Biol., 2016, 6940283 (2016) https://doi.org/10.1155/2016/6940283
Trapana J, Weinerman J, Lee D, Sedani A, Constantinescu D, Best TM, Hornicek FJ, Hare JM. Cell-based therapy in the treatment of musculoskeletal diseases. Stem Cells Transl. Med., 13, 959–78 (2024) https://doi.org/10.1093/STCLTM/SZAE049
Garg P, Singhal S, Kulkarni P, Horne D, Malhotra J, Salgia R, Singhal SS. Advances in non-small cell lung cancer: Current insights and future directions. Journal of Clinical Medicine, 13, 4189 (2024) https://doi.org/10.3390/JCM13144189
Kim M, Shin M, Zhao Y, Ghosh M, Son YO. Transformative impact of nanocarrier-mediated drug delivery: Overcoming biological barriers and expanding therapeutic horizons. Small Science, 4, 2400280 (2024) https://doi.org/10.1002/smsc.202400280
Xu Z, Xie Y, Chen W, Deng W. Nanocarrier-based systems for targeted delivery: Current challenges and future directions. MedComm (Beijing), 6, e70337 (2025) https://doi.org/10.1002/mco2.70337
Basak A, Ghosh S, Ganguly D, Garain S, Ghosh R, Choudhury A, Deka H, Sarmah J. Current trends and future perspectives of natural polymer loaded nanoparticle based drug delivery system for the management of inflammatory bowel disease. Journal of Applied Pharmaceutical Research, 11(4), 01-09 (2023) https://doi.org/10.18231/j.joapr.2023.11.4.1.9
Rahman MM, Islam MR, Akash S, Harun-Or-Rashid M, Ray TK, Rahaman MS, Islam M, Anika F, Hosain MK, Aovi FI, Hemeg HA, Rauf A, Wilairatana P. Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: At a glance. Biomedicine & Pharmacotherapy, 153, 113305 (2022) https://doi.org/10.1016/J.BIOPHA.2022.113305
Jiang Y, Zhou Y, Tian Y, Nabavi N, Ashrafizadeh M, Conde J, Li Z, Guo L. Conductive polymers in smart wound healing: From bioelectric stimulation to regenerative therapies. Mater. Today Bio, 34, 102114 (2025) https://doi.org/10.1016/J.MTBIO.2025.102114
Zahmanova G, Aljabali AAA, Takova K, Minkov G, Tambuwala MM, Minkov I, Lomonossoff GP. Green biologics: Harnessing the power of plants to produce pharmaceuticals. International Journal of Molecular Sciences, 24, 17575 (2023) https://doi.org/10.3390/IJMS242417575
Sairam AB, Sanmugam A, Pushparaj A, Mahesh Kumar G, Sundarapandian N, Balaji S, Nallal M, Park KH. Toxicity of polymeric nanodrugs as drug carriers. ACS Chemical Health & Safety, 30, 236–50 (2023) https://doi.org/10.1021/ACS.CHAS.3C00008
Dalbanjan NP, Korgaonkar K, Eelager MP, Gonal BN, Kadapure AJ, Arakera SB, Kumar SKP. In-silico strategies in nano-drug design: Bridging nanomaterials and pharmacological applications. Nano TransMed, 4, 100091 (2025) https://doi.org/10.1016/J.NTM.2025.100091
Bae H, Ji H, Konstantinov K, Sluyter R, Ariga K, Kim YH, Kim JH. Artificial intelligence-driven nanoarchitectonics for smart targeted drug delivery. Advanced Materials, 37, e10239 (2025) https://doi.org/10.1002/ADMA.202510239
Siddique S, Chow JCL. Recent advances in functionalized nanoparticles in cancer theranostics. Nanomaterials, 12, 2826 (2022) https://doi.org/10.3390/NANO12162826
Sangshetti JN, Deshpande M, Zaheer Z, Shinde DB, Arote R. Quality by design approach: Regulatory need. Arabian Journal of Chemistry, 10, S3412–25 (2017) https://doi.org/10.1016/J.ARABJC.2014.01.025
Dienstmann R, Rodon J, Tabernero J. Biomarker-driven patient selection for early clinical trials. Curr. Opin. Oncol., 25, 305–12 (2013) https://doi.org/10.1097/CCO.0B013E32835FF3CB
Davis KD, Aghaeepour N, Ahn AH, Angst MS, Borsook D, Brenton A et al. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: Challenges and opportunities. Nature Reviews Neurology, 16, 381–400 (2020) https://doi.org/10.1038/s41582-020-0362-2
Hassan YM, Wanas A, Ali AA, El-Sayed WM. Integrating artificial intelligence with nanodiagnostics for early detection and precision management of neurodegenerative diseases. Journal of Nanobiotechnology, 23, 668 (2025) https://doi.org/10.1186/S12951-025-03719-X
Published
How to Cite
Issue
Section
Copyright (c) 2026 Shishupal Kumar, Muneesh Kanaujaya, Pallavi Chand, Ashish Singh Chauhan, Vikash Jakhmola
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
